LLY vs TMO
LLY: Eli Lilly is a global pharmaceutical innovator leading the market in metabolic health, including diabetes and obesity treatments, alongside a diverse portfolio of oncology and immunology therapies. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | LLY | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1,169.60 | $651.98 | |
| Market cap | $1.10T | $241.1B | |
| P/E as of 2026-10-08 | 39.25 | 35.10 | TMO lower |
| PEG as of 2026-10-08, 3-year EPS CAGR to FY2025 | 0.80 | 169.13 | LLY lower |
| Net margin FY2025, SEC XBRL | +31.7% | +15.0% | LLY higher |
| Operating margin FY2025, SEC XBRL | n/a | +17.4% | |
| ROE FY2025, SEC XBRL | +77.8% | +12.6% | LLY higher |
| ROA FY2025, SEC XBRL | +18.4% | +6.1% | LLY higher |
| Debt / equity as of 2026-09-03 | 1.62 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-09-03 | +49.6% | +7.2% | LLY higher |
| Revenue CAGR (3y) SEC XBRL | +31.7% | -0.3% | LLY higher |
| Dividend yield as of 2026-09-03 | +0.6% | +0.3% | LLY higher |
| Dividend streak (yrs) SEC XBRL | 10 | 14 | TMO higher |
| Beta as of 2026-09-03 | 0.55 | 0.77 | |
| 1-year return as of 2026-10-08 close | +38.3% | +21.6% | LLY higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.